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Abstract: Metoprolol (a cardio-selective β1-blocker) has been shown to reduce insulin sensitivity in 
‘healthy’ individuals by 14-27%. It is regularly used in the Christchurch Hospital intensive care unit 
(ICU), but may unintentionally reduce insulin sensitivity and thus exacerbate stress-hyperglycaemia. This 
study used model-based methods to quantify the effect of metoprolol on insulin sensitivity in critically ill 
patients. 
A model-based measure of insulin sensitivity was used to quantify changes between two matched 
retrospective cohorts of 17 ICU patients. All patients were admitted to the Christchurch hospital ICU 
between 2005 and 2007 and spent at least 24 hours on the SPRINT glycaemic control protocol. 
A 9.7% reduction in whole-cohort median insulin sensitivity was seen between the control cohort and 
patients receiving metoprolol with a median dose of 100mg/d per patient. Comparing percentile patients 
as a surrogate for matched patients, reductions in median insulin sensitivity of less than 4% were 
observed for the 25th, 50th and 75th-percentile patients. These cohort and percentile patient reductions are 
less than the 14-27% reductions reported in ‘healthy’ subjects. 
The limited reduction of insulin sensitivity in critically ill patients could be a result of moderation of the 
physiological impact of metoprolol due to already reduced levels of peripheral glucose uptake and insulin 
receptor sensitivity. This limited reduction is not expected to have any clinical impact on the level of 
tight glycaemic control achieved with the SPRINT protocol. 
Keywords: Biomedical system modeling, simulation and visualization; Control of physiological and 
clinical variables; Cellular, metabolic, cardiovascular, neuro-systems 
1. INTRODUCTION 
Studies have shown that metoprolol reduces insulin 
sensitivity (SI) when used to treat essential hypertension in 
otherwise healthy individuals (Jacob et al., 1996, Pollare et 
al., 1989). However, to the authors’ knowledge there is no 
data about whether this effect extends to critically ill patients. 
The aim of this research was to determine to what extent this 
effect occurs in critically ill patients who are already 
relatively insulin resistant due to their condition. 
Metoprolol is a commonly used beta-blocker in the 
Christchurch intensive care unit (ICU). It is a cardio-selective 
inhibitor of the β1-adrenergic receptor and is indicated for 
use in several diseases of the cardiovascular system. Use of 
metoprolol may unintentionally reduce insulin sensitivity and 
thus exacerbate stress-hyperglycaemia.  
Critically ill patients exhibit marked insulin resistance 
compared to healthy people. Increased secretion of counter-
regulatory hormones stimulate endogenous glucose 
production and reduces peripheral insulin sensitivity, 
resulting in hyperglycaemia (Black et al., 1982, McCowen et 
al., 2001, Mizock, 2001). Tight control of blood glucose to 
normal levels has been shown to reduce mortality and organ 
failure (Chase et al., 2010, Chase et al., 2008, Krinsley, 2003, 
Van den Berghe et al., 2006, Van den Berghe et al., 2001) 
Tight glycaemic control (TGC) is already difficult to achieve 
in critically ill patients due to their insulin resistant state, and 
may be made even more difficult by treatment with 
metoprolol. 
Three studies have investigated the effects of metoprolol on 
insulin sensitivity using the gold-standard euglycaemic-
hyperinsulinaemic clamp method (Falkner et al., 2008, Jacob 
et al., 1996, Pollare et al., 1989). Two of the studies (Jacob et 
al., 1996, Pollare et al., 1989) reported reductions in insulin 
sensitivity of 14-27% associated with metoprolol in non-
diabetic individuals when used to treat hypertension. The 
study by Falkner (2008) showed a statistically non-significant 
2% reduction in insulin sensitivity due to metoprolol in type-
2 diabetics. This study uses model-based methods to quantify 
the effect of metoprolol on insulin sensitivity (1/insulin 
resistance) in critically ill patients. 
 
2. SUBJECTS AND METHODS 
2.1 Subjects 
This study was conducted as a retrospective analysis of data 
from patients admitted to the Christchurch Hospital ICU 
between 2005 and 2007. Model-based methods were used to 
identify an insulin sensitivity profile for each patient. This 
insulin sensitivity data was then used to quantify differences 
between patients receiving metoprolol and a control cohort.  
Two cohorts of patients were selected from the available 
records. 17 suitable patients were found for the metoprolol 
  
 
cohort. These patients spent at least 24hrs on the SPRINT 
TGC protocol, did not receive any other beta-blockers 
besides metoprolol (oral or intravenous) and did not receive 
glucocorticoid or ACE-inhibitor treatment. The restrictions 
on other treatments significantly reduced the number of 
patients eligible for consideration, however these treatments 
are known to affect glucose metabolism (Henriksen et al., 
2003, Lithell, 1992, Lithell, 1995, Pollare et al., 1989, Pretty 
et al., 2010) and hence may have confounded results. 
 
Table 1. Comparison of the control and metoprolol cohorts. 
Data are shown as median [interquartile range] where 
appropriate. 
 
*p-values calculated with Mann-Whitney U-test. **p-values calculated with 
two-sided Fishers exact test. 
 
Table 2. Diagnostic categories of the control and metoprolol 
cohorts.  
 
A control cohort of 17 patients was chosen to match the 
overall metoprolol cohort statistics such as age, gender, 
APACHE II score (Table 1) and diagnostic category (Table 
2). In addition to not receiving any metoprolol, the control 
patients were also subject to the same limitations on other 
drug treatments and the SPRINT protocol as the metoprolol 
cohort.  
In cases where patients did not receive treatment with 
metoprolol for the entire time they were on SPRINT, insulin 
sensitivity was considered to be affected by the drug for 12 
hours following the last dose. Metabolism of metoprolol is 
extremely variable between patients (Chrysostomou et al., 
2008), however a number of studies have shown that oral 
doses of 100-200 mg/day result in a duration of action for 
heart-rate and blood-pressure effects of 12-24 hours (Åblad et 
al., 1975, Freestone et al., 1982, Johansson et al., 1980, 
Johnsson et al., 1975, Reybrouck et al., 1978). Previous 
investigations have targeted the effects of chronic metoprolol 
dosing on insulin sensitivity, showing that a reduction in SI is 
present even 20 hrs after the last dose (Jacob et al., 1996, 
Pollare et al., 1989). This variable and prolonged effect made 
comparison of the insulin sensitivity within the metoprolol 
cohort between periods on and off the treatment unfeasible as 
there are few hours of data that could confidently be 
considered unaffected by the drug. 
The SPRINT protocol is a simple, lookup-table system 
derived from a model-based controller that modulates insulin 
and nutritional inputs. The protocol titrates insulin doses and 
nutrition rates to patient-specific insulin sensitivity for tight 
glycaemic control (Chase et al., 2008). SPRINT has been 
used in the Christchurch ICU since August 2005 on more 
than 1000 patients. The requirement for the patients in this 
study to be on the SPRINT protocol ensured that they had 
regular and accurate records of blood glucose levels, insulin 
administered and nutrition given. It also ensured the two 
cohorts had clinically very similar levels of glycaemic 
control.  
The use of these patient records was permitted under existing 
ethics approval granted by the Upper South Regional Ethics 
Committee, New Zealand. 
2.2 Model-based insulin sensitivity 
This study used the glucose-insulin system model described 
by Pretty et al. (2010), with a minor change to the 
endogenous insulin secretion term (7) derived from data not 
yet published. The model-based insulin sensitivity has been 
shown to correlate well with the insulin sensitivity index 
(ISI) determined by the gold-standard euglycaemic-
hyperinsulinaemic clamp (r >0.90) (Lotz et al., 2008). 
Implementing this model in Matlab™ (Mathworks, Natick 
MA) with ICU patient data, an SI value was identified every 
hour for every patient while on the SPRINT protocol. In this 
way, 3,369 and 4,126 SI values were obtained for the control 
and metoprolol cohorts respectively. 
The glucose-insulin system model is defined below in (1)-(7). 
The model parameters, rates and constants are as described in 
Pretty et al. (2010), except for nI and VI which have been 
adjusted to 0.03 min-1 and 4.0 L respectively. The values of 
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the parameters k1-3 in (7) are 0.14 mU.L/mmol.min, 
0.0147 L/mmol and 41 mU/min respectively. 
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2.3 Analysis 
Non-parametric statistics (median, interquartile range) were 
used to define the location and spread of insulin sensitivity 
and blood glucose as typical distributions are asymmetric and 
skewed, rendering Gaussian statistics unsuitable (Micceri, 
1989). Cohort statistics were compared using the Mann-
Whitney U-test for continuous data or two-sided Fisher’s 
exact test for categorical data. Insulin sensitivity values were 
compared using cumulative distribution functions (CDFs) 
and the Mann-Whitney U-test for statistical significance. 
CDFs present the entire shape of the distribution, which was 
particularly useful for these skewed data sets (Hart, 2001). P–
values of less than 0.05 were considered significant. 
Overall cohort comparisons of insulin sensitivity were 
possible with the matched cohorts. However, as individual 
patients could not be explicitly matched, percentile patients 
were used as a surrogate for explicit per-patient analyses as 
described by Pretty et al. (2010). Comparisons were made 
between equivalent percentile patients from each cohort. 
 
3. RESULTS 
3.1 Overall cohort analysis 
Insulin sensitivity in patients receiving metoprolol was 
typically lower than control patients in an overall cohort 
comparison. Median insulin sensitivity was reduced 9.7% 
from 4.04x10-4 to 3.65x10-4 L/mU.min (p < 0.05). Figure 1 
shows the CDFs for both cohorts. There was a clear 
separation between the control cohort and the metoprolol 
cohort (while receiving metoprolol) distributions between the 
10th and 90th percentile values. Outside this range, factors 
such as variable metabolism and dosing of metoprolol 
between patients as well as patient condition may be the 
cause of the insulin sensitivity distributions crossing over 
each other. 
3.2 Percentile patient analysis 
Analysis of the percentile patient data showed no statistically 
or clinically significant reduction in insulin sensitivity for 
patients receiving metoprolol. Figure 2 shows the CDFs for 
the 25th, 50th and 75th-percentile patients from both cohorts 
where the differences were 0.5-3.6%. The p-values for 
comparing equivalent curves were all greater than 0.2. 
 
Figure 1. CDF’s of insulin sensitivities for control and 
metoprolol cohorts. The metoprolol cohort had lower insulin 
sensitivity while receiving metoprolol between the 10th and 
90th percentiles. 
 
Figure 2. CDFs of insulin sensitivity for the 25th, 50th and 
75th-percentile patients from the study cohorts. 
The small size of the study cohorts meant that more extreme 
percentile patients were heavily influenced by individual 
outlying members of each cohort. As individual patients were 
not matched analysis of these more extreme examples 
produced no meaningful results. 
 
4. DISCUSSION 
Studies have shown that metoprolol can reduce insulin 
sensitivity 14-27% when used to treat essential hypertension 
in otherwise healthy individuals (Jacob et al., 1996, Pollare et 
al., 1989). A similar study in hypertensive subjects with non-
insulin dependent diabetes mellitus (NIDDM) (Falkner et al., 
2008) reported a statistically non-significant 2% reduction in 
insulin sensitivity associated with metoprolol. The aim of this 
study was to determine whether metoprolol had an effect on 
the insulin sensitivity of critically ill patients who are already 
relatively insulin resistant due to their condition. 
The results presented in this study indicate that metoprolol 
may have a small effect on the insulin sensitivity of critically 
ill patients; however it is unlikely to be clinically significant. 
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A similar study investigating the effects of glucocorticoids on 
critically ill patients (Pretty et al., 2010) used virtual patient 
simulations to show that changes in SI of 25% resulted in no 
clinically significant alterations to the level of glycaemic 
control under the SPRINT TGC protocol. Therefore a 
reduction in SI of 0.5-10% as reported here may also be 
expected to have little clinical impact.  
The dosage received by patients in this study varied between 
individuals and over the course of treatment. However, over 
the entire cohort the median daily dose of metoprolol was 
100 mg/d (IQR: 50-200 mg/d).This dose is comparable to the 
doses of 200, 100 and 50-200 mg/d administered in the 
studies by Pollare et al. (1989), Jacob et al. (1996) and 
Falkner et al. (2008) respectively. Hence the reduction in 
impact of metoprolol on insulin sensitivity is likely not a 
result of the dosing.  
The study by Falkner et al. (2008) added metoprolol to the 
participant’s existing ACE-inhibitor or ARB hypertension 
treatment regime. Recent research has indicated that 
angiotensin-converting enzyme (ACE) inhibitors or 
angiotensin II receptor blockers (ARBs) lead to improved 
insulin sensitivity (Perkins et al., 2008, Lithell, 1992). It is 
therefore possible that reductions in insulin sensitivity 
associated with metoprolol are mitigated by increases in 
insulin sensitivity due to the concomitant use of ACE-
inhibitors and ARBs, resulting in no significant change as 
reported by Falkner et al. (2008). 
The mechanisms by which beta-adrenoceptor antagonist 
treatment (β-blockade) modifies insulin sensitivity are not yet 
understood. Both Pollare et al. (1989) and Jacob et al. (1996) 
suggest a possible haemodynamic explanation for the reduced 
insulin sensitivity. The reduced heart rate and contractility 
due to metoprolol result in reduced blood flow to the skeletal 
muscles. Thus there is lower glucose availability to these 
prime target tissues for glucose disposal at given insulin 
levels (Jacob et al., 1996, Pollare et al., 1989). And an 
apparent reduction in insulin sensitivity as defined by the rate 
of insulin mediated glucose uptake. Jacob et al. (1996) also 
suggest that β-blockade appears to reduce insulin clearance 
rates and the resulting hyperinsulinaemia may downregulate 
insulin receptors, directly lowering insulin sensitivity. The 
actual mechanism of action may be a combination of these 
factors or an as yet unidentified pathway. 
The critical condition of the patients in this study may 
moderate the physiological impact of these proposed 
mechanisms of action. Critically ill patients already have 
significant peripheral insulin resistance (Black et al., 1982) 
and may therefore be less likely to show further large 
reductions caused by reduced blood flow or receptor 
downregulation compared to healthy subjects. This saturation 
of the physiological effect may explain the limited reduction 
of insulin sensitivity in critically ill patients compared with 
‘healthy’ individuals seen in this study. 
A major limitation of using model-based methods is that the 
parameter of interest (SI) is not measured directly and may be 
influenced by modelling errors or un-modelled effects. The 
insulin sensitivity parameter in the model used for this 
research captures the relative net effect of altered endogenous 
glucose production, peripheral and hepatic insulin mediated 
glucose uptake and endogenous insulin secretion. Hence this 
model-based SI represents more of a “whole-body” insulin 
sensitivity. While receptor downregulation is a direct 
modulation of peripheral insulin sensitivity, altered 
haemodynamics result in reduced “whole-body” insulin 
sensitivity rather than a specific reduction at the receptor site. 
Therefore, the suggested metoprolol mediated changes to 
glucose uptake, in addition to the direct effect on insulin 
sensitivity, cause a relative reduction in the model-based SI. 
This model-based SI correlates very well (r>0.90) with 
euglycaemic clamp derived insulin sensitivity, ISI (Lotz et 
al., 2008), providing support for this metric and overall 
analysis. 
 
5.  CONCLUSION 
This research used model-based methods to show that 
metoprolol causes less of a reduction in the insulin sensitivity 
of critically ill patients than in healthy individuals. Both the 
percentile patient and cohort analyses point to reductions in 
insulin sensitivity associated with metoprolol treatment of 
0.5-10%. These cohort and percentile patient reductions are 
less than the 14-27% reductions reported in ‘healthy’ subjects 
and similar to those reported for NIDDM subjects. This 
limited reduction of insulin sensitivity in critically ill patients 
could be a result of moderation of the physiological impact of 
metoprolol due to already reduced levels of peripheral 
glucose uptake and insulin receptor sensitivity. These 
reductions are not expected to have any clinical impact on the 
level of tight glycaemic control achieved with the SPRINT 
protocol. 
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